Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA).
Groups and individuals representing 340B covered entities, meanwhile, praised HRSA for taking a stand against the six drug makers—AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics.
Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA). Groups and individuals representing 340B covered entities, meanwhile, praised HRSA for taking a stand against the six drug makers—AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.